Lixte Biotechnology (LIXT)

Company Profile

Lixte Biotechnology Holdings, Inc. is a biotech company that identifies enzyme targets associated with serious common diseases and then designs novel compounds to attack those targets. Lixte's product pipeline is primarily focused on inhibitors of protein phosphatases, used alone and in combination with cytotoxic agents and/or X-ray and immune checkpoint blockers.

Company profile

Ticker

LIXT, LIXTW

Exchange

NASDAQ

Website

www.lixte.com

CEO

John S. Kovach

Incorporated

Delaware

Location

New York

Fiscal year end

Dec 31

Sector

Manufacturing > Pharmaceutical Preparation Manufacturing

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co • Abbott Laboratories • Teva- Pharmaceutical Industries • Bristol-Myers Squibb • Lilly(Eli) & Co • Viatris • Abbvie • Bausch Health Companies ...

Former names

SRKP 7 INC

SEC CIK

0001335105

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

Lixte Biotechnology, Inc. ...

LIXT stock data

1M 1Y 5Y

Latest filings (excl ownership)

View all

8-K

Lixte Biotechnology Holdings Reports Newly Published Independent Pre-clinical Research

Registration of securities for employees

16 Dec 22

8-K

Regulation FD Disclosure

6 Dec 22

8-K

LIXTE Biotechnology Holdings to Present

2 Dec 22

8-K

Departure of Directors or Certain Officers

8 Nov 22

Submission of Matters to a Vote of Security Holders

11 Oct 22

Latest ownership filings

View all

4/A

der Baan Bastiaan Jeroen van

5 Jan 23

der Baan Bastiaan Jeroen van

Financial summary

Financial statements Chart LIXT financial data

Quarter (USD)	Sep 22	Jun 22	Mar 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 21	Dec 20	Dec 19	Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	6.56 mm	6.56 mm	6.56 mm	6.56 mm	6.56 mm	6.56 mm
Cash burn (monthly)	391.31 k	(no burn)	492.83 k	558.65 k	391.31 k	379.18 k
Cash used (since last report)	2.26 mm	n/a	2.85 mm	3.23 mm	2.26 mm	2.19 mm
Cash remaining	4.30 mm	n/a	3.71 mm	3.33 mm	4.30 mm	4.37 mm
Runway (months of cash)	11.0	n/a	7.5	6.0	11.0	11.5

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q3 2022

LIXT institutional ownership history Ownership history

3.3% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	14	15	-6.7%
Opened positions	4	5	-20.0%
Closed positions	5	2	+150.0%
Increased positions	5	3	+66.7%
Reduced positions	1	4	-75.0%

13F shares	Current	Prev Q	Change
Total value	246.00 k	652.00 k	-62.3%
Total shares	541.08 k	872.91 k	-38.0%
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Sabby Management	99.64 k	$56.00 k	0.0%
Renaissance Technologies	90.66 k	$51.00 k	+58.5%
Clear Street	85.31 k	$4.00 k	NEW
Vanguard	81.13 k	$45.00 k	-3.4%
MS Morgan Stanley	71.05 k	$40.00 k	0.0%
Geode Capital Management	25.79 k	$14.00 k	0.0%
Two Sigma Investments	21.27 k	$12.00 k	+25.5%
Susquehanna International	17.06 k	$1.00 k	NEW
UBS UBS Group AG - Registered Shares	14.80 k	$4.00 k	+233.4%
Warberg Asset Management	14.50 k	$8.00 k	0.0%

Largest transactions	Shares	Bought/sold	Change
Almanack Investment Partners	0.00	-248.08 k	EXIT
Santa Monica Partners	0.00	-166.67 k	EXIT
Clear Street	85.31 k	+85.31 k	NEW
STT State Street	0.00	-35.96 k	EXIT
Renaissance Technologies	90.66 k	+33.48 k	+58.5%
Citadel Advisors	0.00	-30.06 k	EXIT
Susquehanna International	17.06 k	+17.06 k	NEW
Jane Street	0.00	-12.84 k	EXIT
Virtu Financial	12.78 k	+12.78 k	NEW
UBS UBS Group AG - Registered Shares	14.80 k	+10.36 k	+233.4%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

LIXT insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
30 Dec 22	der Baan Bastiaan Jeroen van	Common Stock	Buy	Acquire P	No	No	0.49	10,000	4.90 k	10,000
15 Dec 22	Rene Bernards	Common Stock	Buy	Acquire P	No	No	0.51	15,000	7.65 k	150,000
12 Dec 22	Rene Bernards	Common Stock	Buy	Acquire P	No	No	0.61	10,000	6.10 k	135,000
9 Dec 22	Forman Eric	Common Stock	Buy	Acquire P	Yes	No	0.63	1,112	700.56	-
9 Dec 22	Forman Eric	Common Stock	Buy	Acquire P	Yes	No	0.6271	5,000	3.14 k	-
9 Dec 22	Forman Eric	Common Stock	Buy	Acquire P	Yes	No	0.6	10,000	6.00 k	-